PF-04217903 Clinical Trials

Size	Price	Qty
5mg	USD 110
50mg	USD 470

Clinical Trials

Available clinical repository data for PF-04217903 includes a clinical trial sponsored by Pfizer to investigate the safety, pharmacokinetics, and pharmacodynamics of the compound in patients with advanced solid neoplasms. Although patient enrollment was initiated for this Phase 1 study, recruitment was ultimately terminated. Consequently, there are currently no active or recruiting clinical investigations documented for this small-molecule inhibitor.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00706355	Terminated	Neoplasms	Pfizer	2008-08	Phase 1

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the PF-04217903 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

PF-04217903 selectively binds to the ATP-binding site of the MET tyrosine kinase (c-Met), thereby blocking receptor autophosphorylation and suppressing downstream oncogenic signaling cascades required for cellular survival and proliferation. By inhibiting c-Met-driven biochemical pathways, this small molecule reduces tumor cell viability, providing therapeutic relevance for the management of advanced neoplasms investigated in early-phase clinical studies.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).